dc.contributor.author | Vanden Eynde, Jean Jacques | |
dc.date.accessioned | 2020-04-23T22:43:38Z | |
dc.date.available | 2020-04-23T22:43:38Z | |
dc.date.issued | 2020-04-10 | |
dc.identifier.uri | https://doi.org/10.3390/ph13040065 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1194 | |
dc.description.abstract | COVID-19 (coronavirus disease 2019) is a worldwide outbreak of pneumonia and acute respiratory distress syndrome. It is unambiguously linked to the human–human transmission of a novel coronavirus. Mutagenomic analyses demonstrated that 79.6% of the genome sequences were identical to those found in the coronavirus responsible for the severe acute respiratory syndrome (SARS), which spread in 2002. Hence the classification as 2019-nCoV (n for novel) and the name SARS-CoV-2. Combatting SARS-CoV-2 has emerged as a tremendous challenge, gathering efforts from academia, pharmaceutical companies, hospitals, international organizations, as well as governments and philanthropic associations (e.g., The Council on Foundations). In this Opinion, we give a brief overview of some current and future clinical trials, as they can be found in the U.S. National Library of Medicine of the National Institutes of Health (Bethesda, MD, USA). | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Chloroquine | en_US |
dc.subject | Hydroxychloroquine | en_US |
dc.subject | Lopinavir | en_US |
dc.subject | Ritonavir | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.title | COVID-19: A Brief Overview of the Discovery Clinical Trial | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Research protocol information | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Pharmaceuticals | en_US |